Compounded Semaglutide in 2026: Rules, Risk, Sourcing
The short answer
Compounded semaglutide exists in the gap the FDA shortage list creates: while brand supply is listed as short, compounders may produce versions, with 503B outsourcing facilities held to stricter manufacturing standards than 503A pharmacies. Clinics carry the sourcing risk: vet the pharmacy, document the clinical rationale, and plan for the day the shortage designation ends.
Key takeaways
- The legal basis is the shortage designation; when it changes, the compounding window narrows fast, so build the contingency now.
- 503B facilities follow manufacturing-grade standards; 503A pharmacies compound per-prescription, with wider variability.
- The prescribing clinic owns the client conversation and the documentation when questions arise.
- Pharmacy vetting is a written diligence file, not a price comparison.
Why compounded semaglutide exists
Brand-name semaglutide (Ozempic for diabetes, Wegovy for weight loss) is manufactured exclusively by Novo Nordisk and costs $800 to $1,300 per month at retail. Even with insurance, many clients face $300 to $500 monthly copays. This pricing puts GLP-1 therapy out of reach for most cash-pay weight loss clinic clients. Compounded semaglutide, produced by compounding pharmacies using semaglutide base powder, costs $50 to $150 per month, making affordable GLP-1 weight loss programs possible.
The legal basis for compounding semaglutide is the FDA's drug shortage list. Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may produce copies of FDA-approved drugs when those drugs are on the official shortage list. Semaglutide has been on and off the shortage list since 2022 due to Novo Nordisk's inability to meet surging demand. When the drug is on the shortage list, compounding is permitted. When it comes off, the legal basis for compounding evaporates.
503A versus 503B pharmacies
503A pharmacies
Section 503A compounding pharmacies operate under state pharmacy board oversight. They compound medications based on individual patient prescriptions, each vial is made for a specific named client. 503A pharmacies cannot produce large batches for distribution. Advantages: widely available, lower minimum order quantities. Disadvantages: no FDA oversight of manufacturing practices, no requirement for potency testing on every batch, and quality varies significantly between pharmacies. Some 503A pharmacies produce excellent compounded semaglutide. Others produce product with inconsistent potency, sterility concerns, or incorrect concentrations.
503B outsourcing facilities
Section 503B outsourcing facilities are registered with the FDA and subject to FDA inspection using current good manufacturing practice (cGMP) standards, the same standards applied to pharmaceutical manufacturers. They can produce large batches without individual patient prescriptions. Advantages: FDA-inspected, required to test every batch for potency and sterility, certificates of analysis provided with each shipment. Disadvantages: higher minimum orders, higher per-unit cost (typically 20% to 40% more than 503A), and fewer facilities available. For clinics prescribing compounded semaglutide, 503B sourcing is strongly recommended despite the higher cost. The quality assurance and legal protection justify the premium.
Quality and potency concerns
Independent testing of compounded semaglutide from various pharmacies has revealed concerning inconsistencies: some vials contained 50% to 70% of the labeled dose, some contained 120% to 140% (potentially dangerous at higher doses), and a small percentage showed bacterial contamination. These findings are not universal, many compounding pharmacies produce high-quality product. But the lack of mandatory testing at 503A pharmacies means the clinic has no guarantee of what is in the vial unless the pharmacy voluntarily provides third-party testing results.
Before partnering with a compounding pharmacy, require: a certificate of analysis (COA) for every batch shipped to your clinic, third-party potency testing results (not just in-house testing), sterility testing documentation, beyond-use dating documentation (how long the compounded product remains stable), and references from other clinics they supply. Any pharmacy that cannot or will not provide these documents should be immediately disqualified.
Legal risk for prescribing clinics
Clinics prescribing compounded semaglutide face three categories of legal risk. First, shortage status changes: if the FDA removes semaglutide from the shortage list, compounding pharmacies must stop producing it. Clinics with active clients on compounded semaglutide must transition those clients to brand-name medication or discontinue therapy. This transition can be abrupt. Second, Novo Nordisk enforcement: the manufacturer has aggressively pursued legal action against compounding pharmacies and has publicly stated its intent to protect its patents. While the legal action targets pharmacies (not prescribing clinics), the downstream effect is supply disruption. Third, adverse events: if a client experiences a serious adverse event from compounded semaglutide with incorrect potency, the prescribing clinic shares liability. Sourcing from a 503B facility with documented quality controls significantly reduces this risk.
Contingency planning
Every clinic offering compounded semaglutide should have a documented contingency plan for when compounding is no longer permitted. Options include: transitioning clients to brand-name Wegovy or Ozempic (requires prior authorization for most insurance plans), transitioning to compounded tirzepatide (if it remains on the shortage list), pivoting to non-GLP-1 weight loss protocols (medical nutrition therapy, phentermine, naltrexone-bupropion), and maintaining a 60 to 90 day supply buffer to allow orderly transition rather than abrupt discontinuation. Communicate the contingency plan to clients at enrollment. Transparency about the regulatory landscape builds trust and reduces panic if a transition becomes necessary.
Affordable access with open eyes
Compounded semaglutide has made GLP-1 weight loss therapy accessible to millions of clients who could not afford brand-name pricing. That accessibility is valuable and worth preserving. But it comes with regulatory complexity and quality risk that clinics must manage proactively. Source from 503B facilities, demand documentation, monitor the shortage list, and maintain a contingency plan. The clinics that treat compounded semaglutide as a carefully managed pharmaceutical supply, not a commodity to be sourced at the lowest price, will serve their clients well and protect their business.
The program side (billing, titration visits, retention) runs on Gracero for weight-loss clinics; the billing mechanics are in the semaglutide clinic billing guide.
Frequently asked questions
What should a pharmacy vetting file contain?
The pharmacy's licensure in your state and its own, 503A or 503B status, certificates of analysis for recent lots, sterility and potency testing practices, recall history, and the beyond-use dating they assign. Keep it current and in writing. If a client outcome ever draws scrutiny, the question will be whether your sourcing diligence was documented, not whether the price was good.
How should clinics explain compounded semaglutide to clients?
Plainly and in writing: it is a compounded preparation, not the FDA-approved branded product; it exists under shortage-based compounding rules; and the clinic sources from a vetted pharmacy with documented quality testing. An informed-consent form covering these points, reviewed by counsel, protects both the client relationship and the clinic when headlines about compounding turn hostile.
What happens when the shortage designation ends?
The compounding permission tied to it narrows or disappears on a compliance timeline, and clinics built entirely on compounded pricing face a hard transition. Plan the contingency in advance: branded pathways and prior-authorization support, revised program pricing, and client communication ready to go. Clinics that treat the compounded window as permanent are planning to improvise their most sensitive client conversation.
Is prescribing compounded semaglutide legally risky for a clinic?
It carries manageable but real exposure: the prescriber owns the clinical decision and its documentation, state boards vary in their posture, and the regulatory ground shifts with the shortage list. Risk drops with legitimate prescribing relationships (real exams, labs where indicated, follow-up), documented pharmacy diligence, and honest client consent. Verify your specific setup with counsel and your state board's current guidance.
Content writer and social media specialist. Covers clinic branding, content marketing, and client engagement strategies for aesthetic and wellness businesses.